| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-14 |
| filingDate |
2019-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2021-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2021515040-A |
| titleOfInvention |
Crystal form II of dalloltamide |
| abstract |
The present invention relates to a crystal form of dalorutamide and a method for producing the same. The present invention also relates to a pharmaceutical composition comprising the crystalline form of the daloltamide, preferably in predetermined and / or effective amounts, together with at least one pharmaceutically acceptable additive. The present invention also relates to pharmaceutical compositions containing dalortamide at high drug loading. The pharmaceutical composition of the present invention can be used as a medicine, particularly as a medicine for the treatment of prostate cancer. |
| priorityDate |
2018-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |